Nicotinamide may put a stop to melanoma

d8db36ce-8b2e-463f-8707-3bb46cf6cb77articleimage.jpg

09 Aug 2017 --- Nicotinamide, a form of vitamin B3, has the potential to prevent melanoma in high-risk individuals, according to a review published in the Photodermatology, Photoimmunology & Photomedicine review. Strategies for skin cancer that prevent the need for chemotherapy are extremely important, especially during a time of aging populations and increasing rates of melanoma and non-melanoma skin cancers worldwide, notes the study. The use of nicotinamide, therefore, presents an interesting option for preventing the most dangerous form of skin cancer in the future. The cost of nicotinamide is approximately US$10 per month if taken at 1g per day as recommended. 

Nicotinamide is an amide form of vitamin B3 (niacin), a water-soluble vitamin. According to the study, it can help to reduce or reverse DNA damage, inflammation and immunosuppression caused by ultraviolet radiation.

The first study considered in the review is the ONTRAC (Oral Nicotinamide to Reduce Actinic Cancer) study, a multicenter, phase III, double-blinded placebo-controlled trial in which 386 participants were recruited. At each three-monthly visit, the number of new non-melanoma skin cancers in the nicotinamide group was lower than that in the placebo group, showing between an 18 percent and a 29 percent relative rate reduction. However, the study did not assess the effect on the rate of melanomas.

In comparison, there have been relatively few studies investigating nicotinamide’s impact on melanomas. In one of the few relevant studies, melanoma cell migratory investigations conducted by Kunimoto et al., nicotinamide significantly reduced the invasion of subcutaneously transplanted melanoma cells in immunocompetent mice.

High-dose oral nicotinamide is increasingly being used in clinical practice for the prevention of non-melanoma skin cancers in high-risk, immune competent patients who have already had multiple skin cancers, reports the review. Its protective effects against some of the biological mechanisms important in causing melanoma, such as the aforementioned DNA damage and UV-caused immunosuppression, suggest to researchers that it could also be effective in melanoma prevention.

Based on current clinical evidence of the use of nicotinamide in non-melanoma skin cancers and early in vitro studies conducted with melanocytes and melanoma cells, the study concludes that randomized placebo controlled trials are now warranted to determine its efficacy and safety for melanoma prevention.

“Nicotinamide has been shown in a clinical trial […] to reduce the incidence of non-melanoma skin cancer in high-risk individuals and it would be worthwhile to determine whether it would also be useful for high-risk melanoma patients,” says Dr. Gary Halliday, senior author of the Photodermatology, Photoimmunology & Photomedicine review.

The review, “Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide?” can be found here.

The use of nicotinamide is the latest possible strategy for fighting skin cancer without the need for chemotherapy. A study has recently found that eating a tomato-rich diet cut the risk of skin cancer in half in some cases, while it may also be useful to avoid white wine, which has been associated with higher rates of invasive melanoma among white men and women. Patients with malignant melanoma that has spread have also been advised that diverse gut bacteria could help with immunotherapy treatment. 

Related Articles

Nutrition & Health News

Debut: Califia Farms launches first dairy-free probiotic yogurt

23 Feb 2018 --- Dairy alternatives manufacturer Califia Farms has launched a breakthrough line of dairy-free yogurt drinks made with the Califia Culture Blend. This distinct trio of 10 billion live, active probiotic CFUs is powered by BB-12, a strain developed by Chr. Hansen for dairy alternatives last year. Califia Farms is the first to batch ferment the BB-12 strain in a non-dairy yogurt. 

Food Research

Consumers want industry to deliver on nutritious food, without compromising on quality: survey

23 Feb 2018 --- Consumers across EMEA want the food and beverage industry to focus on developing healthier, more nutritious food, according to new research commissioned by Ingredion. In fact, 60 percent of respondents said they feel this should be manufacturers’ top priority. However, consumers made it clear that the food industry must ensure that food quality and freshness is not sacrificed as a result. 

Nutrition & Health News

BASF targets fatty liver disease with US launch of Hepaxa product

23 Feb 2018 --- BASF is launching Hepaxa to help patients manage non-alcoholic fatty liver disease in what the corporation describes as “the first dedicated product in the US” to potentially assist tens of millions of patients with one of the most common forms of chronic liver disease. And it could begin to “turn around” non-alcoholic fatty liver disease (NAFLD) in as little as six months, according to BASF executives. 

Nutrition & Health News

Collagen peptides: Innovation platforms far from exhausted, says Rousselot exec

22 Feb 2018 --- Boosted by a growing body of scientific research, collagen peptides have risen in popularity over the past years. In fact, Innova Market Insights figures show that there was a +34 percent compound annual growth rate (CAGR) in new product launches for collagen peptides from 2010 to 2016. However, there is still ample room for further growth and research, according to Lisette van Lith, Global Director of Rousselot's Peptan, who spoke with NutritionInsight about her new role and regional inspiration for the usage of collagen peptides. 

Nutrition & Health News

Naturex targets oral care market with microbiota-balancing natural active

22 Feb 2018 --- Naturex has launched Bucovia, a natural bio-guided fractionated active aimed at effectively supporting mouth health. Current oral healthcare solutions include biocides (antiseptic or antibiotic), synthetic ingredients that wipe out both good and bad mouth bacteria and increase the virulence of Candida. Naturex’s new solution is composed of active compounds from Solidago virgaurea, a European plant containing saponins that are effective in controlling the growth of mixed fungal-bacterial biofilms. Bucovia regulates Candida albicans genes involved in biofilm formation and inhibits its bacterial partners. 

More Articles
URL : http://www.nutritioninsight.com:80/news/nicotinamide-may-put-a-stop-to-melanoma.html